Table of Contents
<< Previous Issue | Jul 2022 (Vol: 2022, Issue: 7) | Next Issue >> |
- Section: Licensing
-
Takeda Licenses F-star’s Immuno-oncology Bispecific Antibody Technology
-
Vertex Signs Gene Editing Partnership with Verve for US$466 M
- Section: Mergers & Acquisitions
-
Galapagos Acquires CellPoint and AboundBio for Next-Generation Cell Therapies
-
AstraZeneca Acquires TeneoTwo in US$1.27 B Deal
-
Vertex Buys ViaCyte for Diabetes Stem Cell Treatment
-
Ipsen Acquires Epizyme to Broaden its Oncology Portfolio
- Section: Research & Development
-
Sanofi Signs US$2.54 B Collaboration Deal with Skyhawk Therapeutics for RNA-splicing Modulators
-
Generian and Mitobridge Form Alliance to Develop Novel Small Molecules for Undruggable Targets
-
Merck & Co. Collaborates with Orion to Develop and Commercialise ODM-208 for US$290 M
-
Merck & Co. Pays US$35 M Upfront for Kelun-Biotech’s ADC Oncology Drug